MedTrace Logo

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

NCT06252792 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-04-03

No results posted yet for this study

Summary

At present, there is no prospective study on the treatment of first-relapsed multiple myeloma with daratumumab plus pomalidomide and dexamethasone (Dara-Pd). A prospective, multicenter, open, non-interventional, observational clinical study to evaluate the efficacy and safety of Dara-Pd in patients with first relapse multiple myeloma.

Conditions

Sponsors & Collaborators

  • Affiliated Hospital of Hebei University

    collaborator OTHER

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • First Affiliated Hospital of Jinan University

    collaborator OTHER

  • Sun Yat-Sen University Cancer Center

    collaborator OTHER

  • FengYan Jin

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2026-06-15
Completion
2026-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06252792 on ClinicalTrials.gov